For investors
‘+1 858-221-3304
[email protected]
For media
+1 619-510-1281
[email protected]
‘
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
•
Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis
•
Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up
16% to $2.95
•
Returned $1.0 billion to shareholders through share repurchases and dividends during FY2026, an
increase of more than 70%
Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
SAN DIEGO, August 6, 2026 – Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter
ended June 30, 2026.
“We closed fiscal year 2026 with strong fourth quarter results, reflecting continued momentum of our global
business, sustained demand for our market-leading products, and disciplined execution of our strategy,” said
Resmed’s Chairman and CEO, Mick Farrell.
“Year-over-year, we delivered 9% reported revenue growth, 90 basis points of gross margin expansion, and a
16% increase in earnings per share. For full year 2026, our $1.6 billion in free cash flow enabled us to invest in
innovation, strengthen our market leadership, and return more than $1 billion to our shareholders.”
“As we enter fiscal year 2027, we will leverage our global scale and enhance our digital capabilities to benefit
our patients, providers, and customers. We will use our industry-leading portfolio to improve patient outcomes,
reduce healthcare costs, and drive long-term profitable growth for our shareholders.”
Financial Highlights
•
FY 2026 revenue increased by 10% to $5.7 billion; up 8% on a constant currency basis
•
FY 2026 GAAP gross margin up 170 bps to 61.1%; non-GAAP gross margin up 240 bps to 62.4%
•
FY 2026 GAAP operating margin up 70 bps to 33.4%, non-GAAP operating margin up 180 bps to 36.1%
•
FY 2026 GAAP diluted earnings per share of $10.43; non-GAAP diluted earnings per share of $11.17, an
increase of 17%
•
FY 2026 operating cash flow of $1.8 billion; free cash flow of $1.6 billion
•
Guiding to more than $1.85 billion in capital to be returned to shareholders through share repurchases and
dividends during FY 2027; announced quarterly dividend increase of 10% to $0.66 per quarter
Other Business and Operational Highlights
•
Announced agreement to sell MatrixCare business; transaction expected to close during the first quarter of
Resmed’s fiscal year 2027.
•
Completed acquisition of Noctrix Health, a medical device company selling FDA De Novo classified
wearable therapeutics for Restless Leg Syndrome, or RLS.
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
Page 2 of 10
•
Partnered with ŌURA to expand access to sleep health education and pathways to care, helping more
people sleep better and improve their overall health.
•
Following other successful launches in APAC, EMEA and the Americas, launched AirSense 11 in Taiwan.
Additionally, launched AirCurve 11 ST/ST-A in the U.S. and AirTouch F30i Comfort in Brazil and Chile.
Financial Results and Operating Metrics
Unaudited; $ in millions, except for per share amounts
Revenue
Gross margin
Three Months Ended
June 30,
June 30,
2026
2025
% Change
$
1,464
$
1,348
9%
58.8 %
60.8 %
(200) bps
Non-GAAP gross margin (B)
61.4 %
90 bps
296
86
267
22
11
19
8
291
449
30.7 %
515
35.2 %
383
428
2.64
$
2.95
$
265
455
33.7 %
476
35.3 %
380
375
2.58
2.55
10
(1)
(300) bps
8
(10) bps
1
14
2
16
7
Operating cash flow
455
539
(16)
Free cash flow(C)
404
508
(21)
Research and development expenses
Selling, general, and administrative expenses
Non-GAAP selling, general, and administrative
expenses(B)
Income from operations
Operating margin
Non-GAAP income from operations (B)
Non-GAAP operating margin
Net income
Non-GAAP net income (B)
Diluted earnings per share
Non-GAAP diluted earnings per share (B)
Revenue
Gross margin
62.3 %
106
Constant
Currency (A)
8%
$
$
Twelve Months Ended
June 30,
June 30,
2026
2025
% Change
$
5,653
$
5,146
10 %
61.1 %
59.4 %
170 bps
Non-GAAP gross margin (B)
60.0 %
240 bps
331
993
14
13
12
10
991
1,685
32.7 %
1,763
34.3 %
1,401
1,407
9.51
9.55
12
12
70 bps
16
180 bps
9
16
10
17
9
Operating cash flow
1,108
1,887
33.4 %
2,039
36.1 %
1,523
1,632
10.43
$
11.17
$
1,806
1,752
3
Free cash flow(C)
1,650
1,662
(1)
Research and development expenses
Selling, general, and administrative expenses
Non-GAAP selling, general, and administrative
expenses(B)
Income from operations
Operating margin
Non-GAAP income from operations (B)
Non-GAAP operating margin
Net income
Non-GAAP net income (B)
Diluted earnings per share
Non-GAAP diluted earnings per share (B)
(A)
62.4 %
378
Constant
Currency (A)
8%
1,120
$
$
In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of foreign currency
fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial
information presented. In order to calculate our constant currency information, we translate the current period financial information
using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency
measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange
rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
(B)
See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
(C)
Free cash flow is equal to operating cash flow less purchases of property, plant and equipment.
Page 3 of 10
Discussion of Fourth Quarter Results
All comparisons are to the prior year period unless otherwise noted
•
Strong revenue growth: Revenue increased 9% (8% in constant currency) to approximately $1.5 billion,
driven by strong demand across sleep devices, masks, accessories, and software solutions.
•
Global momentum: Americas Sleep and Breathing Health revenue grew 8%, Rest of World Sleep and
Breathing Health grew 10% in constant currency, and Residential Care Software revenue increased 2% in
constant currency.
•
Healthy profitability: GAAP gross margin of 58.8%. Non-GAAP gross margin increased 90 basis points to
62.3%, predominantly from productivity pipeline execution. The primary difference is our $42 million Astral
field safety notification expenses.
•
Robust earnings growth: GAAP income from operations of $449 million and GAAP diluted earnings per
share of $2.64. Non-GAAP income from operations increased 8% and non-GAAP diluted earnings per
share grew 16% to $2.95, predominantly attributable to strong sales growth and gross margin improvement.
•
Strong cash generation: Operating cash flow totaled $455 million and free cash flow totaled $404 million,
supporting $287 million returned to shareholders through dividends and share repurchases while
maintaining investment in innovation and growth initiatives.
Dividend program
The Resmed board of directors today declared a quarterly cash dividend of $0.66 per share, representing an
increase of 10% over our previous quarterly dividend. The dividend will have a record date of August 20, 2026,
payable on September 24, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common
stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the
Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the
exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The exdividend date will be August 19, 2026, for common stockholders and for CDI holders. Resmed has received a
waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions
between its common stock and CDI registers from August 19, 2026, through August 20, 2026, inclusive.
Webcast details
Resmed will discuss its fourth quarter fiscal year 2026 results on its webcast at 1:30 p.m. U.S. Pacific Time
today. The live webcast of the call can be accessed on Resmed’s Investor Relations website at
investor.resmed.com. Please go to this section of the website and click on the icon for the “Q4 2026 Earnings
Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the
website and available approximately two hours after the live webcast. In addition, a telephone replay of the
conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.)
or +1 201-612-7415 (outside U.S.) and entering the passcode 13761408. The telephone replay will be available
until August 20, 2026.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re
relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to
live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent
software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a
world where every person can achieve their full potential through better sleep and breathing, with care delivered
in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
Page 4 of 10
Safe harbor statement
Statements contained in this release that are not historical facts are “forward-looking” statements as
contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements –
including statements regarding Resmed’s projections of future revenue or earnings, expenses, new product
development, new product launches, new markets for its products, the integration of acquisitions, our supply
chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of
macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual
results to materially differ from those projected or implied in the forward-looking statements. Additional risks and
uncertainties are discussed in Resmed’s periodic reports on file with the U.S. Securities & Exchange
Commission. Resmed does not undertake to update its forward-looking statements.
– More –
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
Page 5 of 10
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(Unaudited; $ in thousands, except for per share amounts)
Three Months Ended
June 30,
June 30,
2026
2025
Net revenue
Cost of sales
Amortization of acquired intangibles (1)
Masks with magnets field safety notification
expenses (1)
Astral field safety notification expenses (1)
Total cost of sales
Gross profit
$
$
$
1,463,647
$
1,347,993
Twelve Months Ended
June 30,
June 30,
2026
2025
$
5,653,443
$
5,146,327
552,245
8,301
520,068
9,367
2,128,040
31,779
2,060,753
32,116
—
(1,512)
—
(1,512)
41,885
602,431
861,216
$
$
—
527,923
820,070
$
$
41,885
2,201,704
3,451,739
$
$
—
2,091,357
3,054,970
Research and development
105,726
86,443
378,285
331,284
Selling, general, and administrative
Acquisition and portfolio review related
expenses (1)
Total selling, general, and administrative
290,655
265,125
1,108,042
991,019
5,628
296,283
2,031
267,156
11,486
1,119,528
2,031
993,050
Amortization of acquired intangibles (1)
Restructuring expenses (1)
Total operating expenses
Income from operations
$
$
10,499
—
412,508
448,708
$
$
11,928
—
365,527
454,543
$
$
45,466
21,745
1,565,024
1,886,715
$
$
45,273
—
1,369,607
1,685,363
$
20,885
$
5,757
$
49,914
$
4,114
Other income (expenses), net:
Interest (expense) income, net
Gain (loss) attributable to equity method
investments
Gain (loss) on equity investments
Other, net
Total other income (expenses), net
Income before income taxes
Income taxes
Net income
Basic earnings per share
Diluted earnings per share
Non-GAAP diluted earnings per share (1)
Basic shares outstanding
Diluted shares outstanding
2,232
1,269
6,955
$
1,001
1,338
25,456
474,164
90,732
383,432
$
(2,533)
(983)
3,510
458,053 $
78,348
379,705 $
(15,014)
(9,154)
32,701
1,919,416 $
396,123
1,523,293 $
$
$
$
2.65
2.64
2.95
$
$
$
2.59
2.58
2.55
10.47
10.43
11.17
$
144,706
144,976
$
$
$
$
146,472
147,037
(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
– More –
145,523
146,054
3,644
$
$
$
(10,299)
(5,256)
(7,797)
1,677,566
276,843
1,400,723
9.55
9.51
9.55
146,716
147,340
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
Page 6 of 10
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited; $ in thousands)
June 30,
2026
June 30,
2025
Assets
Current assets:
Cash and cash equivalents
Accounts receivable, net
Inventories
Prepayments and other current assets
Assets held for sale
Total current assets
Non-current assets:
Property, plant, and equipment, net
Operating lease right-of-use assets
Goodwill and other intangibles, net
Deferred income taxes and other non-current assets
Total non-current assets
Total assets
$
1,469,234
1,036,233
945,805
416,081
$
1,209,450
939,492
927,711
428,952
$
$
457,386
4,324,739
$
$
—
3,505,605
$
581,829
153,167
3,362,312
543,903
4,641,211
8,965,950
$
550,790
167,497
3,511,541
438,958
4,668,786
8,174,391
$
308,923
494,921
29,141
162,911
98,108
259,950
$
278,157
402,253
30,506
166,030
132,274
9,900
$
$
41,156
1,395,110
$
$
—
1,019,120
$
170,951
64,640
137,413
213,028
399,415
985,447
2,380,557
$
$
$
156,803
77,682
153,015
141,520
658,392
1,187,412
2,206,532
764 $
2,190,614
7,255,121
(2,778,591)
(82,515)
6,585,393 $
8,965,950 $
761
2,033,599
6,081,490
(2,073,292)
(74,699)
5,967,859
8,174,391
$
$
$
$
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
Accrued expenses
Operating lease liabilities, current
Deferred revenue
Income taxes payable
Short-term debt
Liabilities held for sale
Total current liabilities
Non-current liabilities:
Deferred revenue
Deferred income taxes
Operating lease liabilities, non-current
Other long-term liabilities
Long-term debt
Total non-current liabilities
Total liabilities
$
$
Stockholders’ equity
Common stock
Additional paid-in capital
Retained earnings
Treasury stock
Accumulated other comprehensive income
Total stockholders’ equity
Total liabilities and stockholders’ equity
$
$
$
– More –
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
Page 7 of 10
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited; $ in thousands)
Three Months Ended
June 30,
June 30,
2026
2025
Cash flows from operating activities:
Net income
Adjustment to reconcile net income to cash provided
by operating activities:
Depreciation and amortization
Amortization of right-of-use assets
Stock-based compensation costs
(Gain) loss attributable to equity method investments,
net of dividends received
(Gain) loss on equity investments
$
Gain on previously held equity investment
Changes in operating assets and liabilities:
Accounts receivable, net
Inventories, net
Prepaid expenses, net deferred income taxes and
other current assets
Accounts payable, accrued expenses, income taxes
payable and other
Net cash provided by (used in) operating activities
Cash flows from investing activities:
Purchases of property, plant, and equipment
Patent registration and acquisition costs
Purchases of intangible assets
Business acquisitions, net of cash acquired
Purchases of investments
Proceeds from exits of investments
Proceeds (payments) on maturity of foreign currency
contracts
Net cash provided by (used in) investing activities
$
$
Cash flows from financing activities:
Proceeds from issuance of common stock, net
Purchases of treasury stock
Acquisition of consolidated subsidiary
Taxes paid related to net share settlement of equity
awards
Payments of business combination contingent
consideration
Repayment of borrowings
Dividends paid
Net cash provided by (used in) financing activities
$
Effect of exchange rate changes on cash
$
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
$
383,432
$
Twelve Months Ended
June 30,
June 30,
2026
2025
379,705
$
1,523,293
$
1,400,723
44,778
10,343
27,458
63,628
10,660
24,751
201,342
42,810
104,348
198,473
37,338
91,661
2,340
(1,000)
(1,269)
2,533
(2,382)
15,014
(3,644)
10,299
(4,353)
—
(4,353)
—
(37,209)
(33,866)
(5,215)
(32,133)
(96,778)
(9,920)
(76,684)
(80,165)
12,150
47,017
(140,260)
82,629
50,558
454,631
$
49,089
538,766
$
172,715
1,805,829
$
90,958
1,751,588
(51,127)
(5,384)
(739)
(325,319)
(2,000)
—
(30,585)
(3,193)
—
(138,578)
(2,013)
250
(156,285)
(18,670)
(2,218)
(350,724)
(28,536)
2,752
(89,865)
(10,777)
—
(139,248)
(6,416)
4,628
918
(383,651) $
40,406
(133,713) $
8,482
(545,199) $
41,633
(200,045)
29,314
(200,000)
30,156
(100,008)
74,503
(700,037)
74,439
(300,025)
—
(10,855)
—
(10,855)
(388)
(590)
(21,833)
(18,077)
—
(5,000)
(87,090)
(263,164) $
905 $
(191,279)
1,660,513
1,469,234 $
—
(5,000)
(77,590)
(163,887) $
35,573 $
276,739
932,711
1,209,450 $
—
(10,000)
(349,662)
(1,007,029) $
6,183 $
259,784
1,209,450
1,469,234 $
(855)
(40,000)
(310,880)
(606,253)
25,799
971,089
238,361
1,209,450
– More –
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
Page 8 of 10
RESMED INC. AND SUBSIDIARIES
Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)
The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from
acquired intangibles and field safety notification expenses and are reconciled below:
Three Months Ended
Twelve Months Ended
June 30, 2026 June 30, 2025 June 30, 2026 June 30, 2025
Revenue
$ 1,463,647
$ 1,347,993
$ 5,653,443
$ 5,146,327
GAAP cost of sales
Less: Amortization of acquired intangibles (A)
Less: Masks with magnets field safety notification
expenses (A)
Less: Astral field safety notification expenses (A)
Non-GAAP cost of sales
$
$
527,923
(9,367)
$ 2,201,704
(31,779)
$ 2,091,357
(32,116)
1,512
—
—
(41,885)
$ 2,128,040
1,512
—
$ 2,060,753
GAAP gross profit
GAAP gross margin
Non-GAAP gross profit
Non-GAAP gross margin
$
$
$
602,431
(8,301)
—
(41,885)
552,245
$
861,216
$
58.8 %
911,402
$
62.3 %
520,068
820,070
$ 3,451,739
$ 3,054,970
60.8 %
61.1 %
59.4 %
827,925
$ 3,525,403
$ 3,085,574
61.4 %
62.4 %
60.0 %
The measures “non-GAAP selling, general, and administrative expenses” and “non-GAAP selling, general, and
administrative expenses as a percentage of revenues” exclude acquisition and portfolio review related
expenses and are reconciled below:
Three Months Ended
Twelve Months Ended
June 30, 2026
June 30, 2025
June 30, 2026
June 30, 2025
$ 1,463,647
$ 1,347,993
$ 5,653,443
$ 5,146,327
GAAP selling, general, and administrative
Less: Acquisition and portfolio review related expenses
296,283
267,156
1,119,528
993,050
(5,628)
(2,031)
(11,486)
(2,031)
Non-GAAP selling, general, and administrative
290,655
265,125
1,108,042
991,019
Revenue
(A)
As a percentage of revenue:
GAAP selling, general, and administrative expenses
20.2 %
19.8 %
19.8 %
19.3 %
Non-GAAP selling, general, and administrative expenses
19.9 %
19.7 %
19.6 %
19.3 %
– More –
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
Page 9 of 10
RESMED INC. AND SUBSIDIARIES
Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)
The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:
Three Months Ended
Twelve Months Ended
June 30, 2026 June 30, 2025 June 30, 2026 June 30, 2025
GAAP income from operations
Amortization of acquired intangibles—cost of sales (A)
Amortization of acquired intangibles—operating
expenses (A)
Restructuring (A)
Masks with magnets field safety notification expenses (A)
Astral field safety notification expenses (A)
Acquisition and portfolio review related expenses (A)
Non-GAAP income from operations
$
$
448,708
8,301
10,499
—
—
41,885
5,628
515,021
$
$
454,543
9,367
$
1,886,715
31,779
11,928
—
(1,512)
—
2,031
476,357 $
45,466
21,745
—
41,885
11,486
2,039,076
$
$
1,685,363
32,116
45,273
—
(1,512)
—
2,031
1,763,271
The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP
net income and GAAP diluted earnings per share in the table below:
GAAP net income
Amortization of acquired intangibles—cost of sales (A)
Amortization of acquired intangibles—operating
expenses (A)
Restructuring expenses (A)
Gain on previously held equity investment(A)
Three Months Ended
June 30, 2026 June 30, 2025
Twelve Months Ended
June 30, 2026 June 30, 2025
$
$
383,432
8,301
10,499
$
379,705
9,367
11,928
1,400,723
32,116
45,273
—
—
21,745
(4,353)
—
—
—
41,885
5,628
—
(1,512)
—
2,031
(21,430)
—
41,885
11,486
—
(1,512)
—
2,031
(21,430)
—
(29,976)
—
—
(17,059)
428,333 $
(5,544)
374,545 $
GAAP diluted shares outstanding
GAAP diluted earnings per share
Non-GAAP diluted earnings per share (A)
144,976
2.64
2.95
147,037
2.58
2.55
(A)
$
—
(4,353)
Masks with magnets field safety notification expenses (A)
Astral field safety notification expenses (A)
Acquisition and portfolio review related expenses (A)
Tax benefit from business cessation(A)
Income tax effect of interest and penalties on income tax
refunds (A)
Income tax effect on non-GAAP adjustments (A)
Non-GAAP net income (A)
$
$
$
1,523,293
31,779
45,466
$
$
$
$
(39,453)
1,631,848 $
(20,448)
1,406,777
146,054
10.43
11.17
147,340
9.51
9.55
$
$
Resmed adjusts for the impact of the amortization of acquired intangibles, restructuring expenses, gains on previously held equity
investments, field safety notification expenses, acquisition and portfolio review related expenses and associated tax effects, in
addition to tax benefits from business cessation, and the tax effect of interest and penalties on tax refunds from their evaluation of
ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of
current operating performance.
Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to
compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and
evaluating the results of operations in the current period and in comparing it to past periods. Resmed believes this information
provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial
reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other
GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include
all the expenses that must be included under GAAP.
– More –
RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026
Page 10 of 10
RESMED INC. AND SUBSIDIARIES
Revenue by Product and Region
(Unaudited; $ in millions, except for per share amounts)
June 30,
2026
Americas (C)
Devices
Masks and other
Total Americas (C)
Rest of World (C)
Devices
Masks and other
Total Rest of World (C)
Global revenue
Total Devices
Total Masks and other
Total Sleep and Breathing Health
Residential Care Software
Total
$
Rest of World (C)
Devices
Masks and other
Total Rest of World (C)
Global revenue
Total Devices
Total Masks and other
Total Sleep and Breathing Health
Residential Care Software
Total
(A)
459
394
853
$
291
148
439
$
$
$
750
542
1,292
$
172
1,464
$
$
$
$
June 30,
2026
Americas (C)
Devices
Masks and other
Total Americas (C)
Three Months Ended
June 30,
(A)
2025
% Change
$
433
359
792
6%
10
8
261
128
389
12 %
16
13
9%
12
10
$
694
487
1,181
8%
11
9
7%
10
8
$
167
1,348
3
9
2
8
Twelve Months Ended
June 30,
%
(A)
2025
Change
Constant
Currency (B)
$
$
(A)
1,768
1,513
3,281
$
1,124
572
1,697
$
$
$
2,892
2,085
4,978
$
676
5,653
$
$
$
$
Constant
Currency (B)
1,654
1,343
2,998
7%
13
9
1,011
497
1,507
11 %
15
13
6%
9
7
$
2,665
1,840
4,505
9%
13
10
7%
12
9
$
641
5,146
5
10
4
8
$
$
(A)
Totals and subtotals may not add due to rounding.
(B)
In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency
fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial
information presented. In order to calculate our constant currency information, we translate the current period financial information
using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency
measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange
rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
(C)
Historically we have presented our geographical split of revenue as “U.S., Canada, and Latin America” and “Combined Europe, Asia,
and other markets”. Effective this quarter, this presentation has been renamed to Americas (formerly U.S., Canada, and Latin
America) and Rest of World (formerly Combined Europe, Asia, and other markets). The methodology for attributing revenue to these
geographies remains unchanged. Revenue from prior periods is consistent and comparable to previous reporting.
– End –